Repositório Digital

A- A A+

The association between sulfonylurea use and all-cause and cardiovascular mortality : a meta-analysis with trial sequential analysis of randomized clinical trials

.

The association between sulfonylurea use and all-cause and cardiovascular mortality : a meta-analysis with trial sequential analysis of randomized clinical trials

Mostrar registro completo

Estatísticas

Título The association between sulfonylurea use and all-cause and cardiovascular mortality : a meta-analysis with trial sequential analysis of randomized clinical trials
Autor Rados, Dimitris Rucks Varvaki
Pinto, Lana Catani Ferreira
Remonti, Luciana Loss Reck
Leitão, Cristiane Bauermann
Gross, Jorge Luiz
Abstract Background Sulfonylureas are an effective and inexpensive treatment for type 2 diabetes. There is conflicting data about the safety of these drugs regarding mortality and cardiovascular outcomes. The objective of the present study was to evaluate the safety of the sulfonylureas most frequently used and to use trial sequential analysis (TSA) to analyze whether the available sample was powered enough to support the results. Methods and Findings Electronic databases were reviewed from1946 (Embase) or 1966 (MEDLINE) up to 31 December 2014. Randomized clinical trials (RCTs) of at least 52 wk in duration evaluating second- or third-generation sulfonylureas in the treatment of adults with type 2 diabetes and reporting outcomes of interest were included. Primary outcomes were all-cause and cardiovascular mortality. Additionally, myocardial infarction and stroke events were evaluated. Data were summarized with Peto odds ratios (ORs), and the reliability of the results was evaluated with TSA. Forty-seven RCTs with 37,650 patients and 890 deaths in total were included. Sulfonylureas were not associated with all-cause (OR 1.12 [95%CI 0.96 to 1.30]) or cardiovascular mortality (OR 1.12 [95%CI 0.87 to 1.42]). Sulfonylureas were also not associated with increased risk ofmyocardial infarction (OR 0.92 [95% CI 0.76 to 1.12]) or stroke (OR 1.16 [95% CI 0.81 to 1.66]). TSA could discard an absolute difference of 0.5% between the treatments, which was considered theminimal clinically significant difference. Themajor limitation of this review was the inclusion of studies not designed to evaluate safety outcomes. Conclusions Sulfonylureas are not associated with increased risk for all-cause mortality, cardiovascular mortality, myocardial infarction, or stroke. Current evidence supports the safety of sulfonylureas; an absolute risk of 0.5% could be firmly discarded.
Contido em PLoS Medicine. San Francisco. Vol. 13, no. 1 (2016), e1001992
Assunto Compostos de sulfoniluréia
Doenças cardiovasculares
Origem Estrangeiro
Tipo Artigo de periódico
URI http://hdl.handle.net/10183/148812
Arquivos Descrição Formato
000998484.pdf (2.877Mb) Texto completo (inglês) Adobe PDF Visualizar/abrir

Este item está licenciado na Creative Commons License

Este item aparece na(s) seguinte(s) coleção(ões)


Mostrar registro completo

Percorrer



  • O autor é titular dos direitos autorais dos documentos disponíveis neste repositório e é vedada, nos termos da lei, a comercialização de qualquer espécie sem sua autorização prévia.
    Projeto gráfico elaborado pelo Caixola - Clube de Criação Fabico/UFRGS Powered by DSpace software, Version 1.8.1.